#United States #Spyre Therapeutics #IBD treatment #Waltham #biotech company

Spyre Therapeutics: Recent Inducement Awards to Non-Executive Employees

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a leading biotechnology company in the IBD treatment landscape, announced on June 6, 2025, that its independent Compensation Committee has authorized the issuance of stock options to three non-executive employees. This decision is part of Spyre's strategy to enhance employee acceptance of their roles within the company through equity inducement awards.

The approved stock options allow the purchase of a total of 50,200 shares of common stock, underscoring Spyre's commitment to attracting and retaining top talent in the competitive biotech industry. These options are granted under the company's 2018 Equity Inducement Plan, which was updated to include provisions aiding in serving the needs of the company's growing workforce.

Each stock option carries a 10-year term and will allow the employees to exercise their options at a price of $15.40, corresponding with the closure of Spyre's stock on Nasdaq on June 2, 2025. A unique vesting structure is in place; one-fourth of the shares will vest after a year from the employee's start date. The remainder will vest monthly in subsequent months, provided the employees remain with Spyre throughout these periods.

This strategic move aligns with Nasdaq Listing Rule 5635(c)(4), designed to ensure that the compensation packages offered are significant enough to incentivize acceptance of employment by prospective staff, especially in high-demand fields like biotechnology. By providing employees with an avenue to own a part of the company through stock options, Spyre aims not only to enhance engagement but also to foster a sense of ownership and accountability among its new hires.

About Spyre Therapeutics

Spyre Therapeutics is at the forefront of developing advanced therapies for inflammatory bowel disease (IBD) and other immune-mediated conditions. The company focuses on utilizing cutting-edge antibody engineering to improve treatment efficacy and patient convenience. Among its innovative pipeline are extended half-life antibodies targeting critical pathways associated with immune responses, specifically α4β7, TL1A, and IL-23.

As a clinical-stage company, Spyre continues to push boundaries within the biotech realm, leveraging rational therapeutic combinations to enhance the quality of life for patients suffering from complex immune disorders. For further insights into their groundbreaking work and products, interested individuals can visit their official website at www.spyre.com.

This recent initiative of offering inducement awards not only reflects Spyre's robust growth and future potential but also demonstrates its commitment to investing in people who will contribute to its mission of transforming healthcare for immune-mediated diseases.